[{"id":"22c9a347-6084-448c-8e14-d13087fa8660","acronym":"MST01-AZN-05","url":"https://clinicaltrials.gov/study/NCT06366451","created_at":"2025-02-25T15:09:09.368Z","updated_at":"2025-02-25T15:09:09.368Z","phase":"Phase 1","brief_title":"PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC","source_id_and_acronym":"NCT06366451 - MST01-AZN-05","lead_sponsor":"Presage Biosciences","biomarkers":" TMB • MSI","pipe":"","alterations":" ","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tilatamig samrotecan (AZD9592) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/22/2024","start_date":" 05/22/2024","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-01-20"}]